Evidence map›Paper›PMID 27317743›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Promiscuous or discriminating: Has the favored mRNA target of Fragile X Mental Retardation Protein been overlooked?

Aoife C McMahon, Michael Rosbash

Abstract readComment
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Aoife C McMahonEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 15D, United Kingdom; aoifem@ebi.ac.uk.
Michael RosbashHoward Hughes Medical Institute, Brandeis University, Waltham, MA 02453.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Fragile X Messenger Ribonucleoprotein 1Fragile X SyndromeHumansIntellectual DisabilityNerve Tissue ProteinsRNA-Binding ProteinsRNA, MessengerFragile X Messenger Ribonucleoprotein 1Nerve Tissue ProteinsRNA-Binding ProteinsRNA, Messenger

Identifiers

PMID27317743
PMCPMC4932994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.